Skip to main content
. 2018 Oct 23;4:57. doi: 10.1038/s41421-018-0058-6

Table 2.

Primary, secondary, and other related outcomes, according to ADRB2 Arg16Gly (A > G)

Outcome AA genotype AG genotype GG genotype HRa (95% CI) or ORb P value
(N = 919) (N = 1112) (N = 355) AG/GG vs. AA
Primary composite outcome—no. (%)
  Death from cardiovascular causes or heart transplantation 129 (14.0) 209 (18.8) 81 (22.8) 1.49 (1.21–1.83) <0.001
  Death from cardiovascular causes 124 (13.5) 193 (17.4) 74 (20.8) 1.44 (1.16–1.79) 0.001
Secondary outcomes—no. (%)
  Death from any cause 138 (15.0) 226 (20.3) 84 (23.7) 1.50 (1.22–1.83) <0.001
  First hospitalization for cardiovascular causes 243 (26.4) 355 (31.9) 110 (31.0) 1.26 (1.08–1.48) 0.003
  First hospitalization for any cause 317 (34.1) 482 (43.3) 130 (36.6) 1.30 (1.13–1.49) <0.001
  Recurrence of heart failure 228 (24.8) 304 (27.3) 99 (27.9) 1.15 (0.98–1.36) 0.086
Other related outcomes—no. (%)
  New onset of stroke 12 (1.3) 23 (2.1) 5 (1.4) 1.41 (0.72–2.78) 0.320
  Improvement in NYHA class 505 (55.0) 557 (50.1) 170 (47.9) 1.22 (1.03–1.45) 0.021

NYHA New York Heart Association

aHR, hazard ratios and P value were calculated with the use of stratified Cox proportional hazard models adjusting with gender, age, and history of hypertension

bImprovement in heart function was analyzed as a binary outcome with the use of logistic regression model to calculate the odds ratio and P value